RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer

BACKGROUND: Around 15–20% of primary breast cancers are characterized by HER2 protein overexpression and/or HER2 gene amplification. Despite the successful development of anti-HER2 drugs, intrinsic and acquired resistance represents a major hurdle. This study was performed to analyze the RANK pathwa...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanz-Moreno, Adrián, Palomeras, Sonia, Pedersen, Kim, Morancho, Beatriz, Pascual, Tomas, Galván, Patricia, Benítez, Sandra, Gomez-Miragaya, Jorge, Ciscar, Marina, Jimenez, Maria, Pernas, Sonia, Petit, Anna, Soler-Monsó, María Teresa, Viñas, Gemma, Alsaleem, Mansour, Rakha, Emad A., Green, Andrew R., Santamaria, Patricia G., Mulder, Celine, Lemeer, Simone, Arribas, Joaquin, Prat, Aleix, Puig, Teresa, Gonzalez-Suarez, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008631/
https://www.ncbi.nlm.nih.gov/pubmed/33785053
http://dx.doi.org/10.1186/s13058-021-01390-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008631/
https://www.ncbi.nlm.nih.gov/pubmed/33785053
http://dx.doi.org/10.1186/s13058-021-01390-2

Ejemplares similares